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Summary
To asses fracture risk, bone mineral density (BMD) measured by dual-energy X-ray absorptiome-
try (DXA) is the most commonly used tool. The search for clinical risk factors is also advised and 
can provide a 10-year fracture probability (FRAX model). Another important determinant of bone 
strength is bone remodeling. High bone remodeling rates have been associated with a higher 
fracture risk and bone turnover markers (BTM) may offer dynamic information about skeletal sta-
tus independent of BMD. The efficacy of antiresorptive agents in fracture prevention goes beyond 
what can be predicted by BMD especially in the beginning of the treatment. Inhibition of bone 
remodeling itself is certainly an important mechanism by which antiresorptive agents can rapidly 
reduce fracture risk. Thus, it seems quite logical to use BTM in patients with bone disease. It can 
also become a valuable surrogate marker in fracture prediction. However, BTM’s pre-analytical 
and analytical variability should always be considered. Arq Bras Endocrinol Metab. 2010;54(2):99-105
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Sumário
O método mais utilizado para avaliação do risco de fraturas é a densitometria óssea pela téc-
nica de DXA (absorciometria por raios-X duo-energética). A pesquisa de condições clínicas de 
risco também é recomendada e fornece uma estimativa da probabilidade de fratura em 10 anos 
(modelo FRAX). Outro fator importante é o grau de remodelação óssea. Um aumento da taxa 
de remodelação tem sido associado a um maior risco de fraturas e aumento dos marcadores 
ósseos. A medida desses marcadores fornece informação adicional independente da densito-
metria. A eficiência das medicações antirreabsortivas na prevenção de fraturas não é explicada 
apenas pelo aumento da densidade óssea. A menor remodelação óssea é um mecanismo que 
pode explicar a redução da taxa de fraturas principalmente no início do tratamento. A utilização 
desses marcadores nas doenças ósseas e na predição de fraturas torna-se lógica. No entanto, 
para interpretá-los corretamente sua variação pré-analítica e analítica deve ser considerada. Arq 
Bras Endocrinol Metab. 2010;54(2):99-105
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introDuction
Ten years have passed since we first published in the Brazilian Archives of Endocrinology and Metabo-
lism a review article on bone turnover markers (BTM) 
and their practical application (1). In the meantime, 
evolution on this subject has been tremendous with 
better understanding of bone physiology, development 
of new biochemical markers and new assays along with 
cumulative research on how BTM can be used in the 
assessment of bone disease and its treatment. Among 
bone disorders, osteoporosis is far more common and 
corresponds to a major health issue mainly because it 
leads to increased susceptibility to fractures. 
The rationale of all osteoporosis therapies concen-
trates in one primary endpoint which is fracture preven-
tion. The main issue regarding drug efficacy is how one 
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can evaluate fracture rate reduction. To do so, there 
is need of an observational period (usually years) and 
monitoring of a high number of patients in a specific 
population (regarding age and sex differences) (2,3). 
For this reason, there is a necessity for a surrogate mark-
er, i.e., a tool intended to predict a clinical endpoint 
(fracture rate). The importance of surrogate markers 
in osteoporosis was recently discussed by Bouxsein 
and Delmas (4). They recommend that an ideal surro-
gate marker must have specific characteristics: biologi-
cal plausibility (i.e., relation between biomarkers and 
pathogenetic mechanisms leading to increased skeletal 
fragility); association between biomarker and fracture 
in the target population; biomarkers can change con-
sistently in response to therapy, preferably in a predict-
able and dose-dependent fashion that agrees with the 
known mechanism of action of the therapeutic inter-
vention; changes in biomarkers with treatment explain 
a substantial proportion of the antifracture efficacy.
The most widely used tool in osteoporosis diag-
nosis and follow-up is bone mineral density (BMD) 
measured by dual-energy X-ray absorptiometry (DXA) 
which has a strong correlation with fracture risk (5,6). 
BMD measurement can certainly provide useful infor-
mation but holds some restrictions: the differences in 
bone density detected by DXA are gradual and a period 
of 1 or 2 years is usually necessary to identify significant 
changes after therapy has started. In addition, adher-
ence to medication is a well-known problem in osteo-
porosis patients as in any other chronic asymptomatic 
disease (7). To wait at least one year to verify BMD 
changes with treatment is not the most effective way to 
incite patient adherence. Furthermore, the absence of 
BMD increase does not imply absence of therapeutic 
response. Indeed, BMD represents an important but 
not exclusive dimension of bone strength. For example, 
a women aged 75 years is four to seven times more 
likely to experience a fracture than a woman aged 45 
years with the same BMD (8).
In attempt to better estimate fracture risk the World 
Health Organization (WHO) developed the FRAX 
tool which calculates a 10 year probability of osteopo-
rotic fracture based on clinical risk factors such as body 
mass index, fracture history, parental fracture history, 
presence of secondary causes of osteoporosis, use of 
glucocorticoids as well as smoking status and alcohol 
consumption with or without BMD measurements (9). 
Unfortunately, in Brazil we are unable to use the FRAX 
tool because specific epidemiologic data is lacking. 
An important determinant of bone strength that 
is not assessed by BMD or clinical risk factors is bone 
turnover. High bone turnover is associated with more 
severe forms of osteoporosis and an increased frac-
ture risk. Hence, BTM can reflect the dynamic nature 
of bone formation and resorption in a process that is 
usually coupled. Inhibition of bone remodeling itself 
is certainly another mechanism by which antiresorp-
tive agents can rapidly reduce fracture risk before BMD 
changes (10). Additionally, BTM can independently 
provide a tool for monitoring response to therapy af-
ter only 2-3 months (11,12). Therefore, bone turnover 
assessment emerges as a valuable surrogate marker in 
osteoporosis. Their clinical use, advantages and limita-
tions will be discussed below.
Bone turnover marKerS anD remoDeling 
Biology
Bone is a dynamic tissue that is continually renewed 
by a process called bone turnover. A variety of circulat-
ing and local factors act on osteoblasts (bone forming 
cells) to initiate remodeling. The osteoblasts signal for 
differentiation and maturation of osteoclast precursors 
(bone resorbing cells) which carry out dissolution of 
bone matrix constituents leading to the development 
of a resorptive cavity. After a short period of 2-3 weeks 
resorbing osteoclasts undergo apoptosis and osteo-
blasts move into the resorption cavity laying down a ce-
ment line (osteoid), synthesizing new matrix which will 
undergo further mineralization. The bone formation 
process takes several months and as new bone is made 
some osteoblasts are buried in the matrix and become 
osteocytes. This special type of cell can transduce me-
chanical signals necessary for adaptative modeling and 
remodeling in face of changing loads (13). 
Depending upon their origin, BTM are classified as 
formation or resorption markers. If bone physiology is 
preserved, formation and resorption are coupled phases 
and BTM changes in parallel. In many bone diseases, 
this coupling is lost and bone resorption prevails over 
bone formation leading to increased bone turnover. 
The major condition in which this imbalance occurs 
is in post-menopausal osteoporosis when resorption 
markers tend to be higher than formation markers 
(14). On the other hand, conditions like osteopetrosis 
display an opposite state in which formation markers 
are much more elevated than resorption markers. The 
selection of which BMT to use should be based on the 
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physiopathological process occurring in each bone dis-
order or in the mechanism of action of a specific drug, 
when used to monitor treatment. 
Bone formation marKerS
Procollagen i extension peptides
Type I collagen is synthesized by osteoblasts as the pre-
cursor molecule (procollagen) with extension peptides 
in the carboxy (C) and amino (N) ends. These exten-
sions are cleaved by proteases during collagen extra-
cellular metabolism giving rise to N-terminal (PINP) 
and C-terminal (PICP) propeptides of type I collagen 
(Figure 1). They go into the circulation as a trimeric 
form which is rapidly converted in its monomeric form 
and represents a marker of type I collagen synthesis 
(15). Different assays can measure both monomeric 
and trimeric forms. PINP measurement has practical 
advantages of a low diurnal variability, its circulating 
levels are not significantly influenced by food intake 
(patient does not need to be fasting) and it is primarily 
metabolized by the liver with clearance unaffected by 
renal dysfunction (16,17). 
pyrophosphate which inhibits mineral crystallizations 
and acts as a calcium-binding protein. It has a half-life 
of 1-2 days making it less sensitive to circadian varia-
tion, and it is not influenced by renal dysfunction (19).
osteocalcin 
Osteocalcin is the most abundant non-collagen protein 
found in bone. Its structure is monomeric and contains 
49 aminoacid and three-gamma-carboxyglutamic acid 
residues which are responsible for the calcium-binding 
properties of the molecule. During osteoid synthesis, 
osteocalcin is released by osteoblasts and it is involved 
primarily in bone mineralization. A small fraction of os-
teocalcin is released into the circulation and has a circa-
dian rhythm peaking at 4 a.m. It is also cleared by the 
kidney and its levels are affected by renal dysfunction. 
Osteocalcin has a short half-life of less than an hour and 
is quickly degraded so that intact molecules and frag-
ments coexist in circulation (20). There are different 
assays to measure the intact peptide and/or its frag-
ments making comparison between them difficult.
Bone reSorPtion marKerS
telopeptides of type i collagen
These specific peptides are degradation products of 
the non-helical region of type I collagen in the amino- 
terminal region (NTX) and the carboxy-terminal region 
(CTX) produced by osteoclasts during bone resorption 
(Figure 2). NTX and CTX can be measured in either 
serum or urine. The serum levels are influenced by cir-
cadian rhythm and food intake therefore samples must 
be collected at the same time of the day (in the morn-
ing) and in fasting conditions (21). The 24-hour urine 
collection has the advantage of overcoming circadian 
changes and is less sensitive to dietary interferences, 
although patients may find it difficult to collect urine 
properly. Increasingly the automated CTX serum as-
say has become more available and is replacing urinary 
NTX because of its simplicity and robust performance. 
Reference intervals should be age and sex-specific.
Pyridinium cross-links
The cross-links (aldehyde links between lysine or hy-
droxylysine residues) are formed between collagen 
molecules (Figure 2) and are released into circulation 
when collagen is catabolized. They follow a circadian 
N-Protease
N-Propeptide 
(PINP)
C-Propeptide 
(PICP)
C-Protease
Collagen Triple Helix
figure 1. The catabolism of procollagen extension peptides by proteases 
during collagen formation leads to PICP and PINP production. 
Bone-specific alkaline phosphatase
There are several isoforms of alkaline phosphatase orig-
inating from many tissues, mainly liver and bone in a 
proportion of 50% each in normal subjects. The auto-
mation of specific immunoassays for bone-specific alka-
line phosphatase (BSAP) has improved in recent years 
but there is a significant cross-reactivity of 15% with the 
liver form which can be clinically relevant in patients 
with liver disease (18). BSAP is produced by osteoblasts 
during the synthesis of the collagen matrix and increas-
es local concentration if inorganic phosphate destroys 
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rhythm and are higher early in the morning and are 
less influenced by diet. There are two types of cross-
links currently available in serum and urine: Pyridin-
oline (which is less specific and can be derived from 
cartilage, tendons and blood vessels) and Deoxypyridi-
noline (more specific and found in bone and dentin). 
Nowadays immunoassays are preferred instead of high-
performance liquid chromatography (HPLC) used in 
the past (22,23).
ice bath. If stored at -20oC, BTMs are stable for several 
months. Exercise should be avoided preceding sample 
collection because it can increase bone turnover (26). 
Age and sex strongly influence BTM. Values are signifi-
cantly higher in children and post-menopausal women 
when compared to adults. Reference ranges adjusted for 
age and sex must be used for better interpretation but 
this information is not always available (27,28). Coex-
istent health conditions such as bed rest and immobil-
ity, bone metastases, acromegaly and thyrotoxicosis (all 
of them increasing bone resorption) may change bone 
turnover (29,30). A recently sustained fracture alters 
bone turnover. Bone formation and resorption markers 
increase as early as a minimum of 4 months after the 
fracture, reflecting bone healing (31). 
Drugs can modify bone turnover, predominantly in 
case of corticosteroid use. They promptly inhibit bone 
formation with a fall in osteocalcin, PINP and BSAP. 
The use of corticosteroids (prednisone 5 mg or equiva-
lent) can already decrease bone formation. Higher dos-
es (more than 7.5 mg prednisone daily or equivalent 
exceeding 3 months) not only decreases bone forma-
tion and but also increases bone resorption (32,33). 
The use of thiazolinediones can alter bone turnover 
mainly decreasing bone formation by induced activa-
tion of PPAR in mesenchymatous cells promoting their 
differentiation into adipocytes in preference to osteo-
blasts (34). 
Another important issue to be considered is BTM 
interpretation is the Least Significant Change (LSC) of 
each marker. LSC calculation includes pre-analytical and 
analytical variations by using standard statistic methods 
providing a range of values that a given test must exceed 
to conclude that a true biological effect is happening in 
opposition to the measurement error (35). Recent guide-
lines have suggested that a decrease of at least 30% for se-
rum markers and 50%-60% of urinary markers need to be 
observed to suggest that a biological event has occurred 
(36). For instance, patients treated with alendronate that 
exhibit a decrease greater that 30% in BSAP had significant 
lower risk of spine or hip fracture compared with those 
with BSAP changes below 30% from baseline (it is impor-
tant to remember that bone resorption and formation are 
coupled) (37). With risedronate therapy, improvement in 
the rates of vertebral fractures were noted when changes 
greater than 60% from baseline in urinary CTX and chang-
es greater than 40% in urinary NTX were observed (38). 
In teriparatide trials changes greater than 40% in PINP 
should occur before a biological effect may be inferred, 
NTX Mature collagen
Pyridinium crosslinks (PYD and DPD) 
CTX
figure 2. The catabolism of mature collagen by osteoblasts produces 
telopeptides and pyridinium crosslinks.
acid phosphatase
Osteoclasts produce an acid phosphatase isoenzyme 
which is not inhibited by tartrate called type 5 tartrate 
resistant acid phosphatase band 5b (TRAP 5b). This 
enzyme is present in the osteoclast’s ruffled border 
membrane and in the resorptive space. Increased TRAP 
5b levels have been described in high bone turnover 
states like Paget’s disease and bone metastasis. Recent-
ly, due to assay evolution, TRAP 5b is becoming one 
of the BTM used for prediction of high bone turnover 
with a significant correlation with BMD loss (24).
recommenDationS in Btm analySiS anD 
interPretation 
For practical reasons, serum samples are more used than 
urine samples when measuring BTM. Fasting is recom-
mended and blood samples should be obtained in early 
morning. Bone resorption peaks in the second half of 
the night (between 3 and 7 a.m.) and has its nadir in 
the late afternoon (25). Bone formation has less cir-
cadian variability. The time between sample collection, 
centrifugation and storage shoud be no longer than 4 
hours. All samples must be transported in refrigerated 
conditions to assure their stability. Osteocalcin is very 
sensitive to temperature and should be handled in an 
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although some evidence suggests that this limit should be 
at least 20% (39,40). Thus, the need of specific reference 
intervals in different ages and establishment of LSC could 
be obstacles in the use of BTM in clinical practice. There 
are growing efforts to define these intervals for each BTM 
considering the within-subject and between-subject varia-
tion so that serial measurements may provide clinical in-
sights into bone metabolism changes.
clinical value of Btm aSSeSSment
The association between higher bone turnover rate and 
the risk of fracture has been confirmed in several pro-
spective and cohort studies. Higher levels of resorption 
markers are associated with a two-fold increase of ver-
tebral and non-vertebral fractures compared to women 
with normal BTM levels in a population older than 65 
years of age (41,42) and younger than 65 years (43). 
Interestingly, osteopenic women with high BTM lev-
els are at risk of fracture similar to that of osteoporotic 
women. But osteopenic women with normal BTM 
have a low fracture risk comparable to post-menopausal 
women with normal BMD (44). Additionally, increased 
urinary levels of deoxypyridinoline were associated 
with higher risk of hip fractures in elderly women with 
normal BMD from the EPIDOS cohort (45). Since a 
large proportion of women who suffer fragility fracture 
have a BMD above the defined osteoporotic threshold 
(T-score of -2,5 or less) (46), BTM provide another 
way of assessing fracture risk independent of and com-
plementary to BMD measurements. 
Another potential utility of BTM is using bone 
turnover as a guide to drug selection. For example, 
women with a high turnover rate should receive an-
tiresorptive treatment and those with low remodel-
ing rates could benefit from an anabolic agent. Some 
studies have found a higher fracture reduction with 
bisphosphonates in women with high resorption mark-
ers (47,48). However, there is not enough evidence or 
practical guidelines to recommend this conduct in clini-
cal practice. 
Currently, the chief clinical application of BMT mea-
surements is monitoring response to therapy. Changes 
in BTM during treatment depend on the marker type 
evaluated, cellular mechanism of a drug’s action, its po-
tency and route of administration. Bisphosphonate ad-
ministered orally decreases bone resorption in 3 weeks 
with a nadir after 3-6 months and stable values thereaf-
ter. There is also a decrease in bone formation markers 
with a nadir after 6-12 months. Intravenous bisphos-
phonates and subcutaneous denosumab induces a more 
rapidly dose dependent decrease in bone resorption. 
The higher the dose the lower are the resorption mark-
ers and higher the increase in BMD (49-50). During 
anabolic treatment with teriparatide, for example, an 
increase in bone formation is followed by an increase in 
bone resorption. After 1 month, PINP increases about 
60%-70% above baseline and continues to rise for 3-6 
months and then decreases. A rise in CTX is also ob-
served at a lesser extent (51). Strontium Ranelate has 
modest impact in BTM and slightly increases BSAP and 
slightly decreases serum CTX during initial use, then 
both plateau throughout treatment (52). The changes 
in BTM levels after withdraw of osteoporotic medica-
tion are related to posterior changes in BMD and a 
probable decrease in anti-fracture efficacy (53). This 
could be one of the guiding points in the decision to 
restart therapy or to extend drug suspension without 
the need to wait for a decrease in BMD. Finally, as with 
any relatively asymptomatic disease, adherence to treat-
ment is poor in osteoporosis (nearly 50% at 6 months 
for oral medications) and anti-fracture efficacy is linked 
to continuous treatment (54). It is possible that BMT 
measurements improve adherence to osteoporosis 
treatment since their change occurs much earlier than it 
can be detected by BMD, but this observation has not 
been demonstrated conclusively in clinical trials. 
concluSion
Bone turnover assessment is a valuable tool in manage-
ment of osteoporosis and other bone diseases. Potential 
clinical uses of BTM include prediction of bone loss 
and fracture risk, monitoring drug action and adher-
ence to osteoporosis therapy. Limitations imposed by 
pre-analytical and analytical interferences should always 
be considered. Nevertheless, BTM are increasingly be-
coming good surrogate markers and their association 
with BMD measurement can provide a better view of 
bone status.
Disclosure: both of the authors are part of Fleury Group, São 
Paulo, Brazil.
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